April 29, 2026 a 08:38 pm
TECH: Analysts Ratings - Bio-Techne Corporation
Bio-Techne Corporation operates in a dynamic sector catering to the life sciences and diagnostics markets worldwide. The company's diverse product offerings and innovative solutions strengthen its market position. Analyst ratings show a current trend of moderate confidence with predominant 'Buy' recommendations, indicating a cautious yet optimistic outlook among market experts.
Historical Stock Grades
The analysis of Bio-Techne Corporation's stock ratings over recent months indicates that analyst sentiment is largely positive. As of the latest data from April 2026, the majority of ratings are 'Buy', suggesting overall market confidence. Notably, there are no 'Sell' or 'Strong Sell' ratings at present.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 9 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over the past months, the sentiment for Bio-Techne has illustrated a trend toward maintaining 'Buy' positions, diminishing the earlier emphasis on 'Strong Buy' ratings. The total number of analyst ratings has remained relatively stable, indicating consistent market interest.
- The substantial reduction in 'Strong Buy' ratings suggests growing caution among analysts.
- The resilience in 'Buy' ratings over several months highlights sustained confidence.
- 'Hold' ratings show minor fluctuations, reflecting certain market uncertainties.
Percentage Trends
Percentage analysis shows a shift in the analyst sentiment from 'Strong Buy' to 'Buy' over the months. This shift indicates a more moderate expectation of the company's growth and stability.
- March 2026: 'Strong Buy' 5.26%, 'Buy' 47.37%, 'Hold' 21.05%, 'Sell' 0%, 'Strong Sell' 0%
- April 2026: 'Strong Buy' 6.25%, 'Buy' 56.25%, 'Hold' 25%, 'Sell' 0%, 'Strong Sell' 0%
- Overall, the data suggests an increasing preference for more conservative ratings.
Latest Analyst Recommendations
The most recent analyst recommendations for Bio-Techne indicate consistent sentiment, with several ratings maintained over recent months. This reflects a stable outlook among multiple prominent financial entities.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-06 | In Line | In Line | Evercore ISI Group |
| 2026-02-06 | Overweight | Overweight | Wells Fargo |
| 2026-02-05 | In Line | In Line | Evercore ISI Group |
| 2026-02-05 | Hold | Hold | Stifel |
| 2026-02-05 | Buy | Buy | UBS |
Analyst Recommendations with Change of Opinion
The past analyst reports demonstrate occasional shifts in opinion, reflecting responsive adjustments to market or company conditions. Notably, upgrades and downgrades in classifications could suggest reassessments based on emerging information.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-05 | In Line | Outperform | Evercore ISI Group |
| 2025-09-03 | Outperform | Sector Perform | RBC Capital |
| 2025-08-21 | Buy | Neutral | Citigroup |
| 2025-04-09 | Sector Weight | Overweight | Keybanc |
| 2025-04-08 | Sector Weight | Overweight | Keybanc |
Interpretation
The prevailing market sentiment towards Bio-Techne is indicative of cautious optimism. The analyst ratings suggest a belief in stable performance with room for growth. However, recent trends point to a shift towards more conservative ratings, reflecting a careful approach given the current economic environment. The stability seen in the rating patterns implies that analysts maintain a consistent outlook on the company's performance.
Conclusion
Overall, the analyst perspective on Bio-Techne Corporation hints at sustained confidence, tempered with prudence. The past year has seen a shift from aggressive 'Strong Buy' ratings towards 'Buy' and 'Hold’, implying a balanced approach. Key trends suggest that while faith in the company's potential remains, analysts advocate a watchful stance, making it crucial for the company to focus on maintaining its competitive edge. The relatively stable sentiment among analysts underscores a consistent expectation of performance, mitigated by uncertainties in the broader market environment.